Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Congress

September 27, 2018 | Daily News

A provision expanding the sunshine law to require drug and medical device makers publicly disclose payments made to health care providers beyond doctors made it into the final version of an opioid bill unveiled by House and Senate negotiators on Tuesday (Sept. 25), despite opposition from the medical device lobby.

September 26, 2018 | Daily News

The cost of health care is the most important issue affecting small business owners as the midterm elections approach, finds a just-released annual survey (Sept. 26) by the National Small Business Association.

September 26, 2018 | Daily News

The final version of opioid legislation excludes brand-drug industry-backed Part D changes, and now brand lobbyists have set their sights on the lame-duck session for getting Congress to lower the industry’s share of seniors’ drug costs.

September 26, 2018 | Daily News

The final opioid legislation unveiled by House and Senate negotiators late Tuesday (Sept. 25) includes two controversial provisions -- one expanding Medicaid payments for opioid-abuse treatment in large inpatient facilities and another allowing non-physician providers to prescribe a drug used to treat opioid addiction.

September 26, 2018 | Daily News

Bicameral negotiators left out of the final opioid legislation a pay-for that would have extended the time kidney-failure patients could stay on private insurance.

September 26, 2018 | Daily News

The final opioid legislation negotiated by House and Senate negotiators includes a number of FDA-focused provisions, including measures to expand the agency’s authorities in international mail facilities; allow the agency to impose certain packaging and disposal requirements for drugs that pose serious risks; and let FDA require labeling changes for drugs when new effectiveness information emerges.

September 26, 2018 | Daily News

Pharmacists will be allowed to tell customers when it is cheaper to fill prescriptions without insurance after the president signs legislation the House has sent to him banning so-called gag orders.

September 25, 2018 | Daily News

The House on Tuesday (Sept. 25) passed its hazard preparedness reauthorization bill by voice vote.

September 23, 2018 | Daily News

Senate Minority Leader Chuck Schumer (D-NY) is the key lawmaker in brand drug makers’ play to get Congress to lower their share of seniors’ drug costs, sources on both sides of the lobbying effort say.

September 21, 2018 | Daily News

The Advanced Medical Technology Association (AdvaMed) President and CEO Scott Whitaker is upset the Senate tucked into its recently passed opioid bill a provision expanding the sunshine law to require that drug and medical device makers also publicly disclose payments made to nurse practitioners, physician assistants and midwives – not just doctors and hospitals – for promotional talks, consulting and other interactions.

September 21, 2018 | Daily News

Rep. Suzan DelBene (D-WA) is drumming up support for a letter that will ask CMS to adjust the low-volume threshold in order to include more providers in the Merit-based Incentive Payment System as part of the final 2019 physician fee schedule – an agency move that would be supported by some stakeholders like Premier and the American Medical Group Association even though the American Medical Association and others want CMS to finalize the exemption as proposed.

September 21, 2018 | Daily News

Sen. Chuck Grassley (R-IA) is pressing FDA to provide more information about its recent spate of warning letters and civil monetary penalties to more than 1,300 e-cigarette companies.

September 21, 2018 |

Brand drug makers have inched closer to getting Congress to lower their share of seniors’ drug costs by adding to opioid legislation an unrelated package that combines the brand-backed Part D measure with watered-down pro-generic legislation and a provision that averts steep drug cost increases for seniors in 2020.

September 20, 2018 | Daily News

Two top Democrats on the House Committee on Oversight and Government Reform want the committee’s chairman, Rep. Trey Gowdy (R-SC), to subpoena HHS and CMS for documents about the Trump administration’s support of Medicaid work requirements.

September 20, 2018 | Daily News

Brand drug makers have inched closer to getting Congress to lower their share of seniors’ drug costs by adding to opioid legislation an unrelated package that combines the brand-backed Part D measure with watered-down pro-generic legislation and a provision that averts steep drug cost increases for seniors in 2020.

September 20, 2018 | Daily News

Senate Judiciary Chair Chuck Grassley (R-IA) remains concerned that CMS isn't doing enough to oversee nursing home quality, and in a Sept. 19 letter asks when the agency plans to evaluate its new electronic survey of nursing home deficiencies and what steps the agency is taking to improve the collection of data needed to track nursing home quality.

September 19, 2018 | Daily News

CMS faces growing pressure to scrap its controversial plan to allow step therapy for Medicare Part B drugs: Dozens of specialty physician groups and state medical societies are seeking congressional leaders' help in getting the Trump administration to reverse course.

September 18, 2018 | Daily News

The American Hospital Association on Tuesday (Sept. 18) touted a new voluntary 340B reporting program as an alternative to legislation to help achieve transparency in the 340B program, but key lawmakers and the pharmaceutical industry disagreed.

September 18, 2018 | Daily News

Despite being omitted from the Senate’s recently approved opioid bill, some rollback of a federal prohibition on using Medicaid funds to pay for substance-abuse treatment in large inpatient facilities may still be included in the final version of opioid legislation slated to be released in coming days, Senate aides say.

September 18, 2018 | Daily News

Sources say brand and generic drug trade groups have agreed in principle on a deal that couples a tweaked version of the generic-backed bill to stop brands from using drug safety requirements to delay competition with brand-backed Part D bills to reduce brands’ contribution to beneficiaries’ donut hole costs and avert the so-called coverage gap “cliff.”

Pages